RECURRENT PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL LYMPHOMA
Clinical trials for RECURRENT PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to boost remission before stem cell transplant
Disease control Recruiting nowThis study tests a two-step treatment for adults with large B-cell lymphoma that came back or didn't respond to initial therapy. First, participants receive tafasitamab (an antibody) plus lenalidomide, then a chemotherapy combo (ICE) plus tafasitamab. The goal is to see if this a…
Matched conditions: RECURRENT PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
Engineered immune cells take on HIV-Linked lymphoma in new trial
Disease control Recruiting nowThis phase 1 trial is testing a CAR-T cell therapy (axicabtagene ciloleucel) in 20 adults with HIV and aggressive B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified to recognize and attack cancer c…
Matched conditions: RECURRENT PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: AIDS Malignancy Consortium • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New drug duo shows promise for Tough-to-Treat lymphoma
Disease control Recruiting nowThis study tests whether combining two targeted drugs—loncastuximab tesirine and mosunetuzumab—can shrink or eliminate tumors in people with diffuse large B-cell lymphoma that has returned or not responded to prior treatment. About 36 adults will receive the drug combination, and…
Matched conditions: RECURRENT PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 13, 2026 16:01 UTC